Advocates For Oral Contraceptive Switch Shop For Pharma Partner
This article was originally published in The Tan Sheet
Executive Summary
A Center for Reproductive Rights report acknowledges work by the Oral Contraceptives Over-the-Counter Working Group, which is positioned to partner on a switch NDA through a $12m grant, and looks comprehensively at the outlook for a daily-use oral contraceptive switch.
You may also be interested in...
Birth Control Primed For Switch
A new paradigm for nonprescription approvals could eliminate the risk of self-selecting a birth control drug, with some contraindications might likely not apparent, by having pharmacists provide counseling and screening or having women use a self-assessment tool with a standard algorithm.
Errors Coughed Up For Dextromethorphan, Guaifenesin In US FDA Electronic Registrations
Three of seven businesses warned since February 2022 about noncompliance with FDA drug reporting requirements have been marketers of OTC cough/cold/congestion formulations made with dextromethorphan or guaifenesin.
US FDA Postpones Advisory Panel Meeting On Oral Phenylephrine GRASE
Change noted without elaboration in update to FDA announcement on Nonprescription Drugs Advisory Committee meeting. CHPA also notes change, saying it’s best for Industry and for consumers.